Aarhus University Seal / Aarhus Universitets segl

Jens Christian Jensenius

Tumor detection with 131I-labeled human monoclonal antibody COU-1 in patients with suspected colorectal carcinoma

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaperJournal articleResearchpeer-review

Standard

Tumor detection with 131I-labeled human monoclonal antibody COU-1 in patients with suspected colorectal carcinoma. / Ditzel, H; Rasmussen, J W; Erb, Karin; Borup-Christensen, P; Titlestad, Ingrid Louise; Lassen, E; Fenger, Christian; Kronborg, O; Jensenius, Jens Christian.

In: Cancer Research, Vol. 53, No. 24, 1993, p. 5920-8.

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaperJournal articleResearchpeer-review

Harvard

Ditzel, H, Rasmussen, JW, Erb, K, Borup-Christensen, P, Titlestad, IL, Lassen, E, Fenger, C, Kronborg, O & Jensenius, JC 1993, 'Tumor detection with 131I-labeled human monoclonal antibody COU-1 in patients with suspected colorectal carcinoma', Cancer Research, vol. 53, no. 24, pp. 5920-8.

APA

Ditzel, H., Rasmussen, J. W., Erb, K., Borup-Christensen, P., Titlestad, I. L., Lassen, E., Fenger, C., Kronborg, O., & Jensenius, J. C. (1993). Tumor detection with 131I-labeled human monoclonal antibody COU-1 in patients with suspected colorectal carcinoma. Cancer Research, 53(24), 5920-8.

CBE

Ditzel H, Rasmussen JW, Erb K, Borup-Christensen P, Titlestad IL, Lassen E, Fenger C, Kronborg O, Jensenius JC. 1993. Tumor detection with 131I-labeled human monoclonal antibody COU-1 in patients with suspected colorectal carcinoma. Cancer Research. 53(24):5920-8.

MLA

Vancouver

Ditzel H, Rasmussen JW, Erb K, Borup-Christensen P, Titlestad IL, Lassen E et al. Tumor detection with 131I-labeled human monoclonal antibody COU-1 in patients with suspected colorectal carcinoma. Cancer Research. 1993;53(24):5920-8.

Author

Ditzel, H ; Rasmussen, J W ; Erb, Karin ; Borup-Christensen, P ; Titlestad, Ingrid Louise ; Lassen, E ; Fenger, Christian ; Kronborg, O ; Jensenius, Jens Christian. / Tumor detection with 131I-labeled human monoclonal antibody COU-1 in patients with suspected colorectal carcinoma. In: Cancer Research. 1993 ; Vol. 53, No. 24. pp. 5920-8.

Bibtex

@article{fe9249f91ddc48cb9e40c474c258cd0b,
title = "Tumor detection with 131I-labeled human monoclonal antibody COU-1 in patients with suspected colorectal carcinoma",
abstract = "A major factor limiting the use of rodent monoclonal antibodies for diagnosis and therapy of cancer is the development of human anti-mouse immunoglobulin antibodies. Here we report a phase I/II immunodetection study of a human monoclonal antibody, COU-1, labeled with 131I. COU-1 is produced by a human-human hybridoma and recognizes a M(r) 43,000 cytokeratin-like protein strongly expressed by adenocarcinomas of the colon, breast, and ovary. Ten patients were given an i.v. infusion of 2 mg of antibody COU-1 labeled with 185 MBq of 131I. No adverse effects or toxicity were detected by conventional clinical tests nor by a complement activation assay for C3d. None of the patients developed antibodies against antibody COU-1 as determined by enzyme-linked immunosorbent assay and agglutination analysis. Tumor detection was successful in 7 of 9 cancer patients. The tenth patient proved to be a true negative. In several instances immunoscintigraphy gave additional or more correct information than conventional detection techniques. Tumors were most clearly outlined at days 5 and 7 after infusion. Primary colorectal carcinomas were detected by planar imaging in the cecum, ascending colon, and rectum with the smallest lesion measuring 3.0 cm in diameter. Immunoscintigraphy revealed multiple liver metastases in 1 of 3 patients. However, the livers of all 3 patients contained significantly more radioactivity (P <0.005) than tumor-free livers of the other patients. Pharmacokinetics was evaluated in all patients. The clearance of 131I-labeled COU-1 from the circulation followed a triphasic pattern; an initial phase [t1/2 = 0.4 +/- 0.4 (SD) h] cleared 23% of the radioactivity followed by a rapid phase with a half-life of 13 +/- 3.8 h. The third phase (beta-phase) exhibited a half-life of 119 +/- 36 h, which is similar to the half-life reported for normal IgM. The human monoclonal antibody COU-1 directed against a predominantly intracellular cancer-associated antigen does not produce toxicity or induce antibody formation and seems to be a promising agent for detecting tumors with immunoscintigraphy.",
keywords = "Animals, Antibodies, Anti-Idiotypic, Antibodies, Monoclonal, Colorectal Neoplasms, Humans, Immunoglobulin G, Immunoglobulin M, Immunohistochemistry, Iodine Radioisotopes, Rabbits, Radioimmunodetection",
author = "H Ditzel and Rasmussen, {J W} and Karin Erb and P Borup-Christensen and Titlestad, {Ingrid Louise} and E Lassen and Christian Fenger and O Kronborg and Jensenius, {Jens Christian}",
year = "1993",
language = "English",
volume = "53",
pages = "5920--8",
journal = "Cancer Research",
issn = "0008-5472",
publisher = "AMER ASSOC CANCER RESEARCH",
number = "24",

}

RIS

TY - JOUR

T1 - Tumor detection with 131I-labeled human monoclonal antibody COU-1 in patients with suspected colorectal carcinoma

AU - Ditzel, H

AU - Rasmussen, J W

AU - Erb, Karin

AU - Borup-Christensen, P

AU - Titlestad, Ingrid Louise

AU - Lassen, E

AU - Fenger, Christian

AU - Kronborg, O

AU - Jensenius, Jens Christian

PY - 1993

Y1 - 1993

N2 - A major factor limiting the use of rodent monoclonal antibodies for diagnosis and therapy of cancer is the development of human anti-mouse immunoglobulin antibodies. Here we report a phase I/II immunodetection study of a human monoclonal antibody, COU-1, labeled with 131I. COU-1 is produced by a human-human hybridoma and recognizes a M(r) 43,000 cytokeratin-like protein strongly expressed by adenocarcinomas of the colon, breast, and ovary. Ten patients were given an i.v. infusion of 2 mg of antibody COU-1 labeled with 185 MBq of 131I. No adverse effects or toxicity were detected by conventional clinical tests nor by a complement activation assay for C3d. None of the patients developed antibodies against antibody COU-1 as determined by enzyme-linked immunosorbent assay and agglutination analysis. Tumor detection was successful in 7 of 9 cancer patients. The tenth patient proved to be a true negative. In several instances immunoscintigraphy gave additional or more correct information than conventional detection techniques. Tumors were most clearly outlined at days 5 and 7 after infusion. Primary colorectal carcinomas were detected by planar imaging in the cecum, ascending colon, and rectum with the smallest lesion measuring 3.0 cm in diameter. Immunoscintigraphy revealed multiple liver metastases in 1 of 3 patients. However, the livers of all 3 patients contained significantly more radioactivity (P <0.005) than tumor-free livers of the other patients. Pharmacokinetics was evaluated in all patients. The clearance of 131I-labeled COU-1 from the circulation followed a triphasic pattern; an initial phase [t1/2 = 0.4 +/- 0.4 (SD) h] cleared 23% of the radioactivity followed by a rapid phase with a half-life of 13 +/- 3.8 h. The third phase (beta-phase) exhibited a half-life of 119 +/- 36 h, which is similar to the half-life reported for normal IgM. The human monoclonal antibody COU-1 directed against a predominantly intracellular cancer-associated antigen does not produce toxicity or induce antibody formation and seems to be a promising agent for detecting tumors with immunoscintigraphy.

AB - A major factor limiting the use of rodent monoclonal antibodies for diagnosis and therapy of cancer is the development of human anti-mouse immunoglobulin antibodies. Here we report a phase I/II immunodetection study of a human monoclonal antibody, COU-1, labeled with 131I. COU-1 is produced by a human-human hybridoma and recognizes a M(r) 43,000 cytokeratin-like protein strongly expressed by adenocarcinomas of the colon, breast, and ovary. Ten patients were given an i.v. infusion of 2 mg of antibody COU-1 labeled with 185 MBq of 131I. No adverse effects or toxicity were detected by conventional clinical tests nor by a complement activation assay for C3d. None of the patients developed antibodies against antibody COU-1 as determined by enzyme-linked immunosorbent assay and agglutination analysis. Tumor detection was successful in 7 of 9 cancer patients. The tenth patient proved to be a true negative. In several instances immunoscintigraphy gave additional or more correct information than conventional detection techniques. Tumors were most clearly outlined at days 5 and 7 after infusion. Primary colorectal carcinomas were detected by planar imaging in the cecum, ascending colon, and rectum with the smallest lesion measuring 3.0 cm in diameter. Immunoscintigraphy revealed multiple liver metastases in 1 of 3 patients. However, the livers of all 3 patients contained significantly more radioactivity (P <0.005) than tumor-free livers of the other patients. Pharmacokinetics was evaluated in all patients. The clearance of 131I-labeled COU-1 from the circulation followed a triphasic pattern; an initial phase [t1/2 = 0.4 +/- 0.4 (SD) h] cleared 23% of the radioactivity followed by a rapid phase with a half-life of 13 +/- 3.8 h. The third phase (beta-phase) exhibited a half-life of 119 +/- 36 h, which is similar to the half-life reported for normal IgM. The human monoclonal antibody COU-1 directed against a predominantly intracellular cancer-associated antigen does not produce toxicity or induce antibody formation and seems to be a promising agent for detecting tumors with immunoscintigraphy.

KW - Animals

KW - Antibodies, Anti-Idiotypic

KW - Antibodies, Monoclonal

KW - Colorectal Neoplasms

KW - Humans

KW - Immunoglobulin G

KW - Immunoglobulin M

KW - Immunohistochemistry

KW - Iodine Radioisotopes

KW - Rabbits

KW - Radioimmunodetection

M3 - Journal article

C2 - 8261404

VL - 53

SP - 5920

EP - 5928

JO - Cancer Research

JF - Cancer Research

SN - 0008-5472

IS - 24

ER -